Keyword: Sandoz

After months of settlement talks—and as it works with HHS against COVID-19—Teva broke off communications with federal prosecutors, reports say.

Despite COVID-19's blow to the ophthalmology market and a new safety flag, Novartis still expects newly launched Beovu to reach blockbuster status.

Ending the sale to Aurobindo marks a hiccup in Novartis' plan to focus more on higher-margin innovative medicines.

Novartis is appealing a patent court loss against Amgen over Enbrel, but Amgen seems likely to prevail, an analyst wrote.

Only weeks after a former exec in its Sandoz unit pleaded guilty to federal charges, Novartis will pony up $195 million to escape price-fixing claims.

To help allay supply chain concerns from the novel coronavirus, Sandoz pledged "stable" pricing on certain generics and antibiotics.

In the second price-fixing plea deal in as many weeks, federal prosecutors snagged a veteran of Novartis' Sandoz unit on conspiracy charges.

Novartis' Sandoz argued that United Therapeutics used an exclusive device deal to improperly shield Remodulin from generics—but a judge didn't buy it.

Aurobindo Pharma reported that the FDA has more concerns following an inspection of a solids formulation plant in India.

GSK’s respiratory blockbuster Advair was once a top target for generics, but now Novartis is axing its copycat program, to the tune of $442 million.